. Author manuscript; available in PMC: 2022 Jan 1.

Published in final edited form as: J Cancer Res Clin Oncol. 2020 Sep 26;147(1):167–175. doi: 10.1007/s00432-020-03395-4

Table 2.

Results of RT-qPCR, proliferation assay for six Liver Cancer cell lines used in the study.

Variables		Liver Cancer cell lines
Variables		SK-HEP-1	PLC-PRF-5	SNU-387	SNU-423	SNU-449	SNU-475
RT-qPCR (Relative gene expression, ±SD).	RNA-MET	5.16±0.29	0.47±0.04	1.66±0.04	1.46±0.15	11.79±2.71	1.38±0.16
RT-qPCR (Relative gene expression, ±SD).	RNA, L1-MET	0.68±0.10	1.35±0.11	8.13±0.83	0.298±0.02	2.49±0.42	4.96±0.82
Western Blot- Relative Band Intensity: Clone D-4, Santa Cruz Biotechnology.	MET Protein (132KD)	0.064	0.017	0.065	0.238	0.005	0.027
Western Blot -Relative Band Intensity: MAB3729, Millipore.	MET Protein (100KD)	1.06	0.014	0.62	0.35	0.5	0.21
Western Blot -Relative Band Intensity: C-28: sc-161, Santa Cruz Biotechnology.	MET Protein (140KD)	2.40	2.0	8.0	4.5	3.33	2.75
Proliferation Assay “Anti-Met Drugs” “IC50,μM, ±SD”.	Crizotinib	8.32±1.44	8.45±0.33	7.98±0.65	4.59±1.09	3.48±0.66	3.74±0.71
Proliferation Assay “Anti-Met Drugs” “IC50,μM, ±SD”.	Tivantinib	5.65±1.20	8.24±0.09	5.12±10	1.31±0.56	0.37±0.21	1.42±0.04